

Contents lists available at [ScienceDirect](http://www.sciencedirect.com)

Biochimica et Biophysica Acta

journal homepage: www.elsevier.com/locate/bbadis

Review

Calcium-mediated mechanisms of cystic expansion[☆]

Shakila Abdul-Majeed, Surya M. Nauli^{*}

Department of Pharmacology, College of Pharmacy, College of Medicine, The University of Toledo, Toledo, OH 43614, USA
 Department of Medicine, College of Medicine, The University of Toledo, Toledo, OH 43614, USA

ARTICLE INFO

Article history:

Received 1 March 2010

Received in revised form 13 September 2010

Accepted 30 September 2010

Available online 6 October 2010

Keywords:

Primary cilia
 Mechanosensor
 Signaling
 Shear stress

ABSTRACT

In this review, we will discuss several well-accepted signaling pathways toward calcium-mediated mechanisms of cystic expansion. The second messenger calcium ion has contributed to a vast diversity of signal transduction pathways. We will dissect calcium signaling as a possible mechanism that contributes to renal cyst formation. Because cytosolic calcium also regulates an array of signaling pathways, we will first discuss cilia-induced calcium fluxes, followed by Wnt signaling that has attributed to much-discussed planar cell polarity. We will then look at the relationship between cytosolic calcium and cAMP as one of the most important aspects of cyst progression. The signaling of cAMP on MAPK and mTOR will also be discussed. We infer that while cilia-induced calcium fluxes may be the initial signaling messenger for various cellular pathways, no single signaling mediator or pathway is implicated exclusively in the progression of the cystic expansion. This article is part of a Special Issue entitled: Polycystic Kidney Disease.

© 2010 Elsevier B.V. All rights reserved.

1. Introduction

Polycystic kidney disease (PKD) is characterized by formation of fluid-filled cysts. For the past decade, many ideas and much hard work have been put forth to understand the disease, although the mechanisms of cyst formation and expansion remain speculations. Based on transmittance, PKD can be simply classified into acquired and hereditary forms. The acquired form of PKD can be found in patients who have had acute renal failure with subsequent dialysis. The majority of PKD cases, however, are transmitted hereditarily from the parents. The two most common hereditary forms of PKD are autosomal dominant PKD (ADPKD) and autosomal recessive PKD (ARPKD). The genes mutated in ADPKD include *PKD1* and *PKD2*, whereas ARPKD is caused by mutation in *PKHD1* gene (OMIMs: #601313, 613095, 263200). The prevalence of ADPKD and ARPKD is 1 in 1000 and 1 in 20,000 live births, respectively.

The products encoded by these PKD genes are called cysto-proteins (Fig. 1), which include polycystin-1 (*PKD1*), polycystin-2 (*PKD2*), and fibrocystin (*PKHD1*). Though the mechanism of cyst formation is still a mystery, abnormal function of these proteins results in cyst formation. In particular, cysto-proteins interact with

one another (Fig. 1). Thus, aberrant functions in any of these cysto-proteins may result in similar pathogenic phenotypes in the kidney, liver, pancreas and possibly other organs. In addition, these three proteins are localized within the same subcellular domain in the cell. Because these proteins are localized and have distinct functions in the primary cilia, ciliary hypothesis has been developed to explain a unifying pathogenic concept for PKD.

In this review, we will discuss calcium signaling as a possible mechanism that contributes to the functions of these cysto-proteins. Dysfunction of any of these proteins may thus interrupt calcium signaling pathways, which may promote abnormal downstream signal transductions of various signaling molecules participating in renal cyst formation.

2. Calcium signaling by primary cilia

When the PKD genes were discovered and cloned [1–3], their functions in cation transport immediately became of considerable interest in understanding the molecular functions of the cysto-proteins. In particular, sequence analysis of polycystin-2 showed putative homologies with other known calcium channels [4]. In addition to their physical and functional interactions with other calcium-regulated proteins [5–7], interactions of cysto-proteins with other calcium channels also provided further insights into the modulation of intracellular calcium signaling [8–12]. Thus, polycystin-2 has long been predicted to regulate cytosolic calcium [13,14], including modulating intraorganelle calcium release [15] and extracellular calcium influx [16].

To function as a calcium channel, polycystin-2 depends on its interaction with polycystin-1 [16,17]. Likewise, proper function of

[☆] This article is part of a Special Issue entitled: Polycystic Kidney Disease.

^{*} Corresponding author. The University of Toledo, Department of Pharmacology, MS 1015, Health Science Campus, HEB 274, 3000 Arlington Ave., Toledo, OH 43614, USA. Tel.: +1 419 383 1910; fax: +1 419 383 1909.

E-mail address: Surya.Nauli@UToledo.Edu (S.M. Nauli).




Fig. 1. Cysto-protein complex. Polycystin-1 and polycystin-2 form a complex with each other at their COOH termini. Functioning as an adaptor protein, Kif bridges the interaction of between fibrocystin and polycystin complex. Figure is reproduced from Kolb et al. [39] with permission.

fibrocystin depends on the indirect interaction with the polycystin complex [18–20]. In addition, activation of polycystin-2 has been found to depend on its interaction with mammalian diaphanous-related forming 1 (mDia1). mDia1 is able to regulate polycystin-2 depending on the membrane potential or voltage levels in the cells. At resting potentials, mDia1 in an autoinhibited state binds to polycystin-2 thereby inhibiting its channel activity. However, at positive potentials, GTP-bound mDia1 releases and thereby allows activation of polycystin-2 [21].

Localization of cysto-proteins to primary cilia further confirms the roles of polycystins and fibrocystin in intracellular calcium signaling. In addition, it further elaborates the molecular functions of cysto-proteins as regulators for intracellular calcium signaling. Most important are the mechanosensory functions of cysto-proteins that have been independently described in the mouse and human kidney epithelia [20,22–27], vascular endothelia [28–30], osteochondrocytes [31,32], cholangiocytes [33,34] and developing nodes [35–37]. It is now generally accepted that localization of these cysto-proteins to the

primary cilia is important and necessary to initiate the first signaling cascade of intracellular calcium [38–40]. This signaling pathway may further provide other complex downstream signaling pathways.

In general, primary cilia are mechanosensory compartments that house many sensory proteins, including the cysto-proteins. Shear stress that produces enough drag force on the cell surface is able to bend the primary cilium (Fig. 2). Subsequently, activation of the polycystins and other interacting proteins in this complex may result in cytosolic calcium increase. This paradigm was established based mainly on *in vitro* studies where cultured kidney cells were challenged with a fluid-flow shear stress [41,42]. The *ex vivo* experiments using isolated gastrulation stage node, perfused tubules and arteries have further confirmed the mechanosensory function of the primary cilium [28,36,43]. In the vascular artery [28], the influx of extracellular calcium initiates the biochemical cascades that lead to production of nitric oxide vasodilator through endothelial nitric oxide (eNOS). This activation of eNOS depends on the contribution or activity of calmodulin, phosphoinositide kinase-3, protein kinase B and calcium-dependent protein kinase (Fig. 3).

In the next sections, we will discuss the downstream pathways that depend, directly or indirectly, on the initial calcium signaling. Because of the complexity in calcium signaling, we will discuss only those pathways that have possible relevance to renal cyst expansion.

3. Signaling by Wnt

Wnt signaling pathways are involved in many aspects of cell development, such as cell polarity determination, cell adhesion, growth, motility, and many others. The Wnt pathway involves a daunting number of secreted Wnt ligands and Frizzled receptors that regulate a large number of Wnt signaling molecules. In the simplest terms, Wnt signaling can activate three distinct pathways (Fig. 4): (1) β -catenin dependent canonical pathway, (2) β -catenin independent non-canonical or PCP (planar cell polarity) pathway, and (3) Wnt-calcium pathway, which can influence both the canonical and non-canonical pathways [44].

Many regulatory proteins involved in Wnt signaling are localized in the primary cilium and base of the cilium, also known as basal body. It is thus speculated that flow-induced cytosolic calcium influx switches off the canonical Wnt pathway and activates the non-canonical Wnt/calcium signaling pathway (Fig. 4). This molecular switch is regulated by inversin, which is a ciliary protein that can turn different Wnt signaling pathways on and off [45]. Of note is that abnormalities in inversin function result in polycystic kidney phenotype.

The zebrafish cystic kidney gene *seahorse* has also been found to be involved in a variety of cilia-mediated processes such as body curvature, kidney cyst formation, left-right asymmetry, and others




Fig. 3. Mechanosensory cilia, cytosolic calcium and nitric oxide production. Bending or activation of the cilia involves mechanosensory polycystin-1 and polycystin-2 complex, which results in biochemical synthesis of NO. The signaling pathway requires extracellular calcium influx (Ca^{2+}), followed by activation of various calcium-dependent proteins including calmodulin (CaM) and protein kinase C (PKC). Together with PKB, CaM and PKC are important downstream molecular components to activate endothelial nitric oxide synthase (eNOS).

including PCP signaling and inhibition of the canonical Wnt signaling [46]. *Seahorse* seems to be essential for a functional non-canonical Wnt signaling. It associates with Dishevelled (Dsh), the divergence point for the canonical Wnt and PCP pathways. The *Seahorse* gene encodes a highly conserved five leucine-rich repeats (LRR) and a leucine-rich repeat cap, from *Drosophila* to humans. One of the leucine-rich repeat proteins, LRRC50, has been found to be conserved in both zebrafish and humans. *Lrrc50* is expressed in all ciliated tissues in




Fig. 2. Primary cilia in signal transduction system. Cilia sense fluid-shear stress on the apical membrane of the cells. Fluid flow that produces enough drag-force on the top of the cells will bend sensory cilia. Bending of cilia will activate the cysto-proteins, resulting in extracellular calcium influx. Figure is reproduced from AbouAlaiwi et al. [38] with permission.




Fig. 4. Mechanosensory cilia, cytosolic calcium and Wnt signaling. Bending or activation of the cilia results in maintaining cytosolic calcium (Ca^{2+}), followed by activation of inversin. Calcium and inversin function as the molecular switches for Wnt signaling pathways. The Wnt canonical pathway involves β -catenin. Both β -catenin and E-cadherin regulate cell differentiation and proliferation. The Wnt non-canonical pathway involves small GTPase rho and JNK, both of which play an important role in planar cell polarity.

zebrafish, resulting in ciliary dysfunction in *lrrc50* mutants. In humans and dog kidney cells, LRRC50 has been shown to localize at the mitotic spindle and cilium, implying it to be a ciliary protein in vertebrates [47].

It is generally accepted that Wnt signaling pathway is not regulated properly in polycystic kidney disease (Fig. 4). In the canonical Wnt pathway, β -catenin in the nucleus mediates many gene induction events, and any deregulation of this pathway can result in uninhibited proliferation of cells [48,49]. It is speculated that flow-induced cytosolic calcium influx is required to turn off the canonical Wnt pathway and activate the non-canonical Wnt/calcium signaling pathway. As such, over-activation of canonical Wnt pathway, by over-production of an activated form of β -catenin for an example, would result in polycystic kidney phenotype [50]. This view is consistent with the profiling gene expression study [51]. A consistently high level of Wnt signaling is observed in cystic tissues from ADPKD patients, but not in tissues which exhibited low level or no cyst formation from the same patients. Furthermore, abnormalities in polycystins enhance activity of Wnt signaling pathway [52–55].

E-cadherin is one of the interacting Wnt signaling molecules, and it plays an essential role in intercellular cell junction assembly. It is required for epithelial polarity and tubule formation. Disruption of E-cadherin could lead to abnormal levels of β -catenin and impeding renal epithelial polarization [54,56]. Furthermore, the protein complex of polycystins, E-cadherin, and β -catenin is interrupted in cyst-lining epithelial cells in ADPKD patients [57]. In addition, the levels of β -catenin in the developing hearts and kidneys of *Pkd1*^{-/-} mouse embryos compared to wild type embryos is decreased [53]. Overall,

the data suggest that interruption in Wnt signaling pathway would result in less differentiated epithelial cells, yielding to proliferation and acceleration of cyst expansion [58].

Planar cell polarity, which involves non-canonical Wnt signaling, has recently been the most discussed topic towards the understanding of renal cysts. Planar cell polarity is principally involved in the development of tissue architectures along a parallel axis, other than the apical–basolateral axis of a renal tubule (Fig. 5). Oriented cell division is thought to be necessary for the elongation of the developing nephron. Abnormalities in the planar cell polarity, as reflected by the mitotic spindle, have been observed in various PKD mouse models [52,59–63]. In these studies, cell division or mitotic spindle orientation within the tubular axis were measured. However, it is currently unclear whether such an alignment can be considered a process toward planar cell polarity [64]. In *Drosophila*, for example, mitotic spindle alignment is achieved only after centrosomes have been properly aligned [65]. Thus, there is a cell-cycle checkpoint for centrosomal positioning. The question remains whether such a checkpoint is disrupted in PKD.

Within the non-canonical Wnt signaling, there is also a huge body of evidence indicating that JNK signaling system is involved in PKD [66–70]. The strongest evidence of non-canonical Wnt signaling, however, came from a study involving Rho small G protein. In the mouse model, mutation in the key regulator of Rho small G protein results in cystic kidney phenotype [71]. Taken together, interruption in Wnt signaling pathway would result in cyst formation due to planar cell polarity defects, and mitotic spindle orientation might be a contributing factor in the process.




Fig. 5. Planar cell polarity and cystic kidney disease. The illustration depicts the mechanism of mitotic spindle formation as an index of planar cell polarity in cyst expansion. (a) Each cilium senses changes in urine flow. This message provides critical calcium signals to the cell. (b) Abnormalities in any of the cysto-proteins results in abnormal ciliary function. (c) The functional abnormality in ciliary sensing results in disorientation of the mitotic spindle, and hence the cell will lose planar cell polarity. (d) Direction of cell division becomes randomized. This will result in increasing tubular diameter, rather than tubular elongation. (e) Budding of a cyst from the renal tubule occurs. The abnormal localizations of epidermal growth factor receptor (EGFR) and Na^+/K^+ ATPase pump are typical characteristics of polycystic kidneys. (f) The cyst is eventually enlarged and expanded further. Multiple cysts within a kidney are illustrated on the bottom left corner. Figure is reproduced from Kolb et al. [39] with permission.

4. Signaling by cAMP/MAPK

Cyclic adenosine monophosphate, or cAMP, has been identified as one of the most important players in cyst progression in both ADPKD and ARPKD (Fig. 6). Two major processes that contribute to the expansion of the renal cysts in polycystic kidney disease are cell proliferation and fluid secretion. cAMP is intimately involved in accelerating both of these processes [72–75]. Tissues from the kidneys, liver, and vascular smooth muscles of PKD animal models exhibit increased levels of cAMP [76–78].

cAMP is known to be one of most important players in effecting hormonal activation of intracellular pathways and is intimately involved in cell proliferation in almost all cell lines. However, cAMP does not produce the same effects in all cell lines. Though cAMP has

been used for several years as an anti-proliferative agent [79,80], cAMP has also been known to stimulate cell proliferation by activating the mitogen activated protein kinase (MAPK) pathway (Fig. 6). For example, cAMP is anti-proliferative in normal tissues, but it stimulates cell proliferation in cystic epithelial cells [73,81,82].

The change in cAMP related phenotype—inhibition of cell proliferation in normal cells and stimulation of cell proliferation in cystic cells—is associated with the amount of intracellular calcium in PKD tissues and cells [82,83]. The imbalance in the cytosolic calcium due to the disruptions in the cysto-proteins promotes abnormal function of phosphodiesterase (Fig. 6). Phosphodiesterase 1 isoforms (PDE1a, PDE1b and PDE1c) are present in especially high levels in the kidneys [84]. Most importantly, the activity of this phosphodiesterase is regulated by intracellular calcium and cAMP. In PKD cells with a low level of




Fig. 6. Cytosolic calcium and cAMP signaling. Under normal conditions, the carboxy terminal tails of polycystin-1 and polycystin-2 interact, which enables calcium entry into the cell. This further stimulates the release of calcium from the calcium stores inside the cell. In the presence of high, steady state levels of calcium, calcium-stimulated phosphodiesterases are capable of degrading cAMP into AMP, thereby controlling the cAMP levels in the cell. The low levels of cAMP are unable to stimulate MAPK pathway. In polycystic kidneys, however, the resulting abnormality in cysto-proteins causes a lower level of intracellular calcium. Hence, the activity of phosphodiesterases is not stimulated and cAMP level increases, leading to activation of B-Raf of MAPK pathway.

intracellular calcium, phosphodiesterase activity is down-regulated. This results in aberrant conversion of cAMP to AMP. The resulting increase in cytosolic cAMP further stimulates the MAPK pathways, which promotes cyst expansion through higher cell proliferation.

In general, cystic epithelia in polycystic kidneys have exhibited high levels of both cAMP and MAPK activity compared to normal cells, resulting in cell proliferation in polycystic kidneys and an inhibition of cell proliferation in normal cells [85,86]. In normal epithelial cells, cAMP agonists inhibit MAPK pathway by blocking activation of Raf-1 (Raf-C) through cAMP-dependent protein kinase (PKA). On the other hand, cAMP was found to stimulate the MAPK pathway in PKD cells, thereby stimulating cell proliferation. This difference has also been observed to result from an increased affinity of cAMP for B-Raf rather than A-Raf and Raf-1 (C-Raf) [82,86]. As mentioned earlier, this change in cAMP-related signaling is also attributed to the level of intracellular calcium. The high levels of cAMP, combined with low levels of calcium fluxes in polycystic kidneys, could further result in a decrease of PI3K/Akt activity, thereby stimulating B-Raf activation and hence activation of the MAPK pathway of Ras/B-Raf/MEK/ERK [83,87,88].

5. Signaling by mTOR

The Ras/Raf/ERK pathway plays another important role in polycystic kidney disease by regulating the mammalian target of

rapamycin (mTOR) pathway through molecular signaling of tuberin (Fig. 7). Tuberin, which is also regulated by Akt, is a GTPase activating protein (GAP). Tuberin regulates the activity of Rheb, a small G-protein belonging to the Ras super family. GTP-bound Rheb is active, while GDP-bound Rheb is inactive. Hamartin and tuberin form a heterodimer which converts Rheb-GTP to Rheb-GDP, thereby inactivating Rheb. Rheb activates mTOR pathway. Hence, tuberin inactivates GTP-bound Rheb and inhibits the mTOR pathway [89–91].

The respective protein products of *TSC1* and *TSC2*, hamartin and tuberin, regulate formation of primary cilia [92,93]. Most importantly, however, analysis of normal and diseased cells from ADPKD patients indicates that the cyst lining epithelial cells exhibit higher levels of mTOR signaling compared to the surrounding normal epithelium [94]. When mTOR pathway is inhibited with rapamycin, many murine models of ADPKD and ARPKD show a decrease in renal cyst expansion [94–100]. The consensus is that the cytoplasmic tail of polycystin-1 directly or indirectly interacts with both mTORC1 complex as well as tuberin, the protein product of *Tsc2* which itself regulates mTORC1. Membrane localization of polycystin-1 and hamartin are therefore able to bind to tuberin, keeping it near the plasma membrane. Thus, membrane bound polycystin-1 is capable of controlling mTORC1 pathway and hence extensive cell proliferation. Disruption of polycystin-1 would imply the activation of the mTORC1 cascade yielding cell proliferation and subsequent cyst formation [101,102].




Fig. 7. Signaling pathway of mTOR. In healthy kidney cells, the cysto-protein complex interacts with tuberin. Hamartin and tuberin form a complex and localize in the basal body. Tuberin is a GTPase activating protein (GAP) which controls the activity of Rheb. Tuberin inactivates Rheb, thereby inhibiting the mTOR pathway. In polycystic kidneys, however, tuberin is no longer protected in this complex and is phosphorylated by Akt, RSK (via ERK). As a result, tubulin is unable to form a heteradimer with hamartin. Hence, tuberin is no longer able to inhibit Rheb, and the mTOR pathway is activated.

In addition, the cysto-proteins are known to contribute to the activation of the Akt/PKB pathway [101,103,104]. Thus, the interaction of Akt and tuberin can further provide an additional regulation of mTOR pathway by the cysto-proteins. Although the role of calcium in mTOR signaling has still not been properly studied in polycystic kidney disease, there is a possibility that calcium-ERK-mTOR pathway could exist. In particular, calcium is known to be associated with cAMP/ERK activity (Fig. 6), and ERK has been implicated in mTOR signaling (Fig. 7). There is no doubt that further studies are needed to dissect the contributions of calcium, ERK and mTOR in cystogenesis.

Interestingly, clinical trials of mTOR inhibitors in ADPKD patients have not yielded much anticipated results [105–107]. The two mTOR inhibitors tested in ADPKD patients were sirolimus and everolimus. Sirolimus was tested on 100 patients (18 to 40 years) exhibiting early stages of the disease, while everolimus was tried on 433 patients in advanced-stage II and III, with a renal baseline volume of 1500 mL. Sirolimus did not show any decrease in total kidney size in humans, though it showed promising results in mouse models. However, the animals were treated with a dose of 5 mg/kg of body weight [94], a dosage that is unsafe for humans, who were administered 2 mg sirolimus for 18 months. No difference in GFR was observed as these patients exhibited the initial stages of the disease [105]. Everolimus, on the other hand, slowed the increase in the total kidney volume without any effect on GFR. After a brief transient period, patients exhibited a rapid decline in GFR [106]. These studies imply that reducing the cyst size need not necessarily improve renal function in these patients.

6. Prospective

Cilia function and structure are important and necessary to maintain the architecture of kidney tissue. Abnormalities in the structure or function of cilia results in PKD. The mechanosensory cilia are crucial in maintaining intracellular calcium signaling. Many cell types, including renal epithelia, use cytosolic calcium as a second messenger to further regulate other cellular homeostasis through a very complex signal transduction system. This signaling system includes Wnt, cAMP-MAPK, Akt, mTOR, and other pathways that are not discussed in this review.

In understanding this complexity, an important lesson is that no single signaling mediator is implicated exclusively in the progression of the cystic expansion. Rather, all of these signaling pathways are intimately connected, thereby regulating the progression of the disease. Nonetheless, only by understanding such a complicated system do we have better insights to attain the most effective way to retard progression of polycystic kidney disease.

Acknowledgments

Due to restricted space, we apologize to those whose work is not described in this review. Authors are grateful for stimulating discussion about primary cilia given by research assistants, graduates, undergraduates and pharmacy students in our laboratory. Authors thank Drs. Robert Kolb, Stefan Somlo, Bradley Yoder, and Jing Zhou for valuable insights and use of their laboratory reagents. Authors also thank Charisse Montgomery for her editorial review of the manuscript.

as well as Maki Takahashi and Shao Lo for use of their figures and illustrations. Work from our laboratory that is cited in this review has been supported by grants from the NIH (DK080640) and the NIH Recovery Act Funds. We are thankful to The University of Toledo research programs, including the *deArce* Memorial Endowment Fund.

References

- [1] Polycystic kidney disease: the complete structure of the PKD1 gene and its protein, The International Polycystic Kidney Disease Consortium, *Cell*, 81, 1995, pp. 289–298.
- [2] T. Mochizuki, G. Wu, T. Hayashi, S.L. Xenophontos, B. Veldhuisen, J.J. Saris, D.M. Reynolds, Y. Cai, P.A. Gabow, A. Pierides, W.J. Kimberling, M.H. Breuning, C.C. Deltas, D.J. Peters, S. Somlo, PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein, *Science (New York, N.Y.)* 272 (1996) 1339–1342.
- [3] C.J. Ward, M.C. Hogan, S. Rossetti, D. Walker, T. Sneddon, X. Wang, V. Kubly, J.M. Cunningham, R. Bacallao, M. Ishibashi, D.S. Milliner, V.E. Torres, P.C. Harris, The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein, *Nat. Genet.* 30 (2002) 259–269.
- [4] Y. Cai, Y. Maeda, A. Cedzich, V.E. Torres, G. Wu, T. Hayashi, T. Mochizuki, J.H. Park, R. Witzgall, S. Somlo, Identification and characterization of polycystin-2, the PKD2 gene product, *J. Biol. Chem.* 274 (1999) 28557–28565.
- [5] P. Delmas, H. Nomura, X. Li, M. Lakkis, Y. Luo, Y. Segal, J.M. Fernandez-Fernandez, P. Harris, A.M. Frischauf, D.A. Brown, J. Zhou, Constitutive activation of G-proteins by polycystin-1 is antagonized by polycystin-2, *J. Biol. Chem.* 277 (2002) 11276–11283.
- [6] Y. Li, N.G. Santos, S. Yu, O.M. Woodward, F. Qian, W.B. Guggino, Polycystin-1 interacts with inositol 1, 4, 5-trisphosphate receptor to modulate intracellular Ca^{2+} signaling with implications for polycystic kidney disease, *J. Biol. Chem.* 284 (2009) 36431–36441.
- [7] S.C. Parnell, B.S. Magenheimer, R.L. Maser, C.A. Rankin, A. Smine, T. Okamoto, J.P. Calvet, The polycystic kidney disease-1 protein, polycystin-1, binds and activates heterotrimeric G-proteins in vitro, *Biochem. Biophys. Res. Commun.* 251 (1998) 625–631.
- [8] C.X. Bai, A. Giamarchi, L. Rodat-Despoix, F. Padilla, T. Downs, L. Tsiokas, P. Delmas, Formation of a new receptor-operated channel by heteromeric assembly of TRPP2 and TRPC1 subunits, *EMBO Rep.* 9 (2008) 472–479.
- [9] M. Kottgen, B. Buchholz, M.A. Garcia-Gonzalez, F. Kotsis, X. Fu, M. Doerken, C. Boehlke, D. Steffl, R. Tauber, T. Wegierski, R. Nitschke, M. Suzuki, A. Kramer-Zucker, G.G. Germino, T. Watanick, J. Prenen, B. Nilius, E.W. Kuehn, G. Walz, TRPP2 and TRPV4 form a polymodal sensory channel complex, *J. Cell Biol.* 182 (2008) 437–447.
- [10] Y. Li, J.M. Wright, F. Qian, G.G. Germino, W.B. Guggino, Polycystin 2 interacts with type I inositol 1, 4, 5-trisphosphate receptor to modulate intracellular Ca^{2+} signaling, *J. Biol. Chem.* 280 (2005) 41298–41306.
- [11] R. Ma, W.P. Li, D. Rundel, J. Kong, H.I. Akbarali, L. Tsiokas, PKD2 functions as an epidermal growth factor-activated plasma membrane channel, *Mol. Cell Biol.* 25 (2005) 8285–8298.
- [12] L. Tsiokas, T. Arnould, C. Zhu, E. Kim, G. Walz, V.P. Sukhatme, Specific association of the gene product of PKD2 with the TRPC1 channel, *Proc. Natl Acad. Sci. USA* 96 (1999) 3934–3939.
- [13] S. Gonzalez-Perrett, K. Kim, C. Ibarra, A.E. Damiano, E. Zotta, M. Batelli, P.C. Harris, I.L. Reislin, M.A. Arnaout, H.F. Cantiello, Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca^{2+} -permeable nonselective cation channel, *Proc. Natl Acad. Sci. USA* 98 (2001) 1182–1187.
- [14] P.M. Vassilev, L. Guo, X.Z. Chen, Y. Segal, J.B. Peng, N. Basora, H. Babakhanlou, G. Cruger, M. Kanazirska, C. Ye, E.M. Brown, M.A. Hediger, J. Zhou, Polycystin-2 is a novel cation channel implicated in defective intracellular Ca^{2+} homeostasis in polycystic kidney disease, *Biochem. Biophys. Res. Commun.* 282 (2001) 341–350.
- [15] P. Koulou, Y. Cai, L. Geng, Y. Maeda, S. Nishimura, R. Witzgall, B.E. Ehrlich, S. Somlo, Polycystin-2 is an intracellular calcium release channel, *Nat. Cell Biol.* 4 (2002) 191–197.
- [16] K. Hanaoka, F. Qian, A. Boletta, A.K. Bhunia, K. Piontek, L. Tsiokas, V.P. Sukhatme, W.B. Guggino, G.G. Germino, Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents, *Nature* 408 (2000) 990–994.
- [17] L. Tsiokas, E. Kim, T. Arnould, V.P. Sukhatme, G. Walz, Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2, *Proc. Natl Acad. Sci. USA* 94 (1997) 6965–6970.
- [18] I. Kim, Y. Fu, K. Hui, G. Moelck, W. Mai, C. Li, D. Liang, P. Zhao, J. Ma, X.Z. Chen, A.L. George Jr., R.J. Coffey, Z.P. Feng, G. Wu, Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function, *J. Am. Soc. Nephrol.* 19 (2008) 455–468.
- [19] I. Kim, C. Li, D. Liang, X.Z. Chen, R.J. Coffey, J. Ma, P. Zhao, G. Wu, Polycystin-2 expression is regulated by a PC2-binding domain in the intracellular portion of fibrocystin, *J. Biol. Chem.* 283 (2008) 31559–31566.
- [20] S. Wang, J. Zhang, S.M. Nauli, X. Li, P.G. Starremans, Y. Luo, K.A. Roberts, J. Zhou, Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia, *Mol. Cell Biol.* 27 (2007) 3241–3252.
- [21] C.X. Bai, S. Kim, W.P. Li, A.J. Streets, A.C. Ong, L. Tsiokas, Activation of TRPP2 through mDia1-dependent voltage gating, *EMBO J.* 27 (2008) 1345–1356.
- [22] V. Chauvet, X. Tian, H. Husson, D.H. Grimm, T. Wang, T. Hiesberger, P. Igarashi, A.M. Bennett, O. Ibragimov-Beskronnaya, S. Somlo, M.J. Caplan, Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus, *J. Clin. Invest.* 114 (2004) 1433–1443.
- [23] S.H. Low, S. Vasanth, C.H. Larson, S. Mukherjee, N. Sharma, M.T. Kinter, M.E. Kane, T. Obara, T. Weimbs, Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease, *Dev. Cell* 10 (2006) 57–69.
- [24] S.M. Nauli, F.J. Alenghat, Y. Luo, E. Williams, P. Vassilev, X. Li, A.E. Elia, W. Lu, E.M. Brown, S.J. Quinn, D.E. Ingber, J. Zhou, Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells, *Nat. Genet.* 33 (2003) 129–137.
- [25] S.M. Nauli, S. Rossetti, R.J. Kolb, F.J. Alenghat, M.B. Consugar, P.C. Harris, D.E. Ingber, M. Lohman-Adham, J. Zhou, Loss of polycystin-1 in human cyst-lining epithelia leads to ciliary dysfunction, *J. Am. Soc. Nephrol.* 17 (2006) 1015–1025.
- [26] C. Xu, S. Rossetti, L. Jiang, P.C. Harris, U. Brown-Glaberman, A. Wandinger-Ness, R. Bacallao, S.L. Alper, Human ADPKD primary cyst epithelial cells with a novel, single codon deletion in the PKD1 gene exhibit defective ciliary polycystin localization and loss of flow-induced Ca^{2+} signaling, *Am. J. Physiol.* 292 (2007) F930–F945.
- [27] C. Xu, B.E. Shmukler, K. Nishimura, E. Kaczmarek, S. Rossetti, P.C. Harris, A. Wandinger-Ness, R.L. Bacallao, S.L. Alper, Attenuated, flow-induced ATP release contributes to absence of flow-sensitive, purinergic Ca^{2+} signaling in human ADPKD cyst epithelial cells, *Am. J. Physiol.* 296 (2009) F1464–F1476.
- [28] W.A. AbouAlaiwi, M. Takahashi, B.R. Mell, T.J. Jones, S. Ratnam, R.J. Kolb, S.M. Nauli, Ciliary polycystin-2 is a mechanosensitive calcium channel involved in nitric oxide signaling cascades, *Circ. Res.* 104 (2009) 860–869.
- [29] S.M. Nauli, Y. Kawanabe, J.J. Kaminski, W.J. Pearce, D.E. Ingber, J. Zhou, Endothelial cilia are fluid shear sensors that regulate calcium signaling and nitric oxide production through polycystin-1, *Circulation* 117 (2008) 1161–1171.
- [30] R.E. Poelmann, K. Van der Heiden, A. Gittenberger-de Groot, B.P. Hierck, Deciphering the endothelial shear stress sensor, *Circulation* 117 (2008) 1124–1126.
- [31] B. Hou, E. Kolpakova-Hart, N. Fukai, K. Wu, B.R. Olsen, The polycystic kidney disease 1 (PKD1) gene is required for the responses of osteochondroprogenitor cells to midpalatal suture expansion in mice, *Bone* 44 (2009) 1121–1133.
- [32] Z. Xiao, S. Zhang, J. Mahlios, G. Zhou, B.S. Magenheimer, D. Guo, S.L. Dallas, R. Maser, J.P. Calvet, L. Bonewald, L.D. Quarles, Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression, *J. Biol. Chem.* 281 (2006) 30884–30895.
- [33] A.I. Masyuk, T.V. Masyuk, P.L. Splinter, B.Q. Huang, A.J. Stroope, N.F. LaRusso, Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca^{2+} and cAMP signaling, *Gastroenterology* 131 (2006) 911–920.
- [34] T.V. Masyuk, B.Q. Huang, C.J. Ward, A.I. Masyuk, D. Yuan, P.L. Splinter, R. Punyashthiti, E.L. Ritman, V.E. Torres, P.C. Harris, N.F. LaRusso, Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat, *Gastroenterology* 125 (2003) 1303–1310.
- [35] B.W. Bisgrove, B.S. Snarr, A. Emrazian, H.J. Yost, Polaris and Polycystin-2 in dorsal forerunner cells and Kupffer's vesicle are required for specification of the zebrafish left-right axis, *Dev. Biol.* 287 (2005) 274–288.
- [36] J. McGrath, S. Somlo, S. Makova, X. Tian, M. Brueckner, Two populations of node monocilia initiate left-right asymmetry in the mouse, *Cell* 114 (2003) 61–73.
- [37] P. Vogel, R. Read, G.M. Hansen, L.C. Freay, B.P. Zambrowicz, A.T. Sands, Situs inversus in *Dpcc/Poll*^{-/-}, *Nme7*^{-/-}, and *Pkd11*^{-/-} mice, *Vet. Pathol.* 47 (2010) 120–131.
- [38] W.A. AbouAlaiwi, S.T. Lo, S.M. Nauli, Primary cilia: highly sophisticated biological sensors, *Sensors* 9 (2009) 7003–7020.
- [39] R.J. Kolb, S.M. Nauli, Ciliary dysfunction in polycystic kidney disease: an emerging model with polarizing potential, *Front. Biosci.* 13 (2008) 4451–4466.
- [40] S.M. Nauli, J. Zhou, Polycystins and mechanosensation in renal and nodal cilia, *Bioessays* 26 (2004) 844–856.
- [41] H.A. Praetorius, K.R. Spring, Removal of the MDCK cell primary cilium abolishes flow sensing, *J. Membr. Biol.* 191 (2003) 69–76.
- [42] B.J. Siroky, W.B. Ferguson, A.L. Fuson, Y. Xie, A. Fintha, P. Komlosi, B.K. Yoder, E.M. Schwiebert, L.M. Guay-Woodford, P.D. Bell, Loss of primary cilia results in deregulated and unabated apical cation entry in ARPKD collecting duct cells, *Am. J. Physiol.* 290 (2006) F1320–F1328.
- [43] W. Liu, N.S. Murcia, Y. Duan, S. Weinbaum, B.K. Yoder, E. Schwiebert, L.M. Satlin, Mechanoregulation of intracellular Ca^{2+} concentration is attenuated in collecting duct of monocilia-impaired orpk mice, *Am. J. Physiol.* 289 (2005) F978–F988.
- [44] R. Habas, L.B. Dawid, Dishevelled and Wnt signaling: is the nucleus the final frontier? *J. Biol.* 4 (2005) 2.
- [45] M. Simons, J. Gloy, A. Ganner, A. Bullerkotte, M. Bashkurov, C. Kronig, B. Schermer, T. Benzing, O.A. Cabello, A. Jenny, M. Mlodzik, B. Polok, W. Driever, T. Obara, G. Walz, Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways, *Nat. Genet.* 37 (2005) 537–543.
- [46] N. Kishimoto, Y. Cao, A. Park, Z. Sun, Cystic kidney gene seahorse regulates cilia-mediated processes and Wnt pathways, *Dev. Cell* 14 (2008) 954–961.
- [47] E. van Rooijen, R.H. Giles, E.E. Voest, C. van Rooijen, S. Schulte-Merker, F.J. van Eeden, LRRC50, a conserved ciliary protein implicated in polycystic kidney disease, *J. Am. Soc. Nephrol.* 19 (2008) 1128–1138.
- [48] V. Singla, J.F. Reiter, The primary cilium as the cell's antenna: signaling at a sensory organelle, *Science (New York, N.Y.)* 313 (2006) 629–633.
- [49] I.R. Veland, A. Awan, L.B. Pedersen, B.K. Yoder, S.T. Christensen, Primary cilia and signaling pathways in mammalian development, health and disease, *Nephron* 111 (2009) 39–53.
- [50] S. Saadi-Kheddouci, D. Berrebi, B. Romagnolo, F. Cluzeaud, M. Peuchmaur, A. Kahn, A. Vandewalle, C. Perret, Early development of polycystic kidney disease in

- transgenic mice expressing an activated mutant of the beta-catenin gene, *Oncogene* 20 (2001) 5972–5981.
- [51] M. Lal, X. Song, J.L. Pluznick, V. Di Giovanni, D.M. Merrick, N.D. Rosenblum, V. Chauvet, C.J. Gottardi, Y. Pei, M.J. Caplan, Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling, *Hum. Mol. Genet.* 17 (2008) 3105–3117.
 - [52] H. Happe, W.N. Leonhard, A. van der Wal, B. van de Water, I.S. Lantinga-van Leeuwen, M.H. Breuning, E. de Heer, D.J. Peters, Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways, *Hum. Mol. Genet.* 18 (2009) 2532–2542.
 - [53] E. Kim, T. Arnould, L.K. Sellin, T. Benzing, M.J. Fan, W. Gruning, S.Y. Sokol, I. Drummond, G. Walz, The polycystic kidney disease 1 gene product modulates Wnt signaling, *J. Biol. Chem.* 274 (1999) 4947–4953.
 - [54] I. Kim, T. Ding, Y. Fu, C. Li, L. Cui, A. Li, P. Lian, D. Liang, D.W. Wang, C. Guo, J. Ma, P. Zhao, R.J. Coffey, Q. Zhan, G. Wu, Conditional mutation of Pkd2 causes cystogenesis and upregulates beta-catenin, *J. Am. Soc. Nephrol.* 20 (2009) 2556–2569.
 - [55] D. Romaker, M. Puetz, S. Teschner, J. Donauer, M. Geyer, P. Gerke, B. Rumberger, B. Dworniczak, P. Pennekamp, B. Buchholz, H.P. Neumann, R. Kumar, J. Gloy, K.U. Eckardt, G. Walz, Increased expression of secreted frizzled-related protein 4 in polycystic kidneys, *J. Am. Soc. Nephrol.* 20 (2009) 48–56.
 - [56] S. Muto, A. Aiba, Y. Saito, K. Nakao, K. Nakamura, K. Tomita, T. Kitamura, M. Kurabayashi, R. Nagai, E. Higashihara, P.C. Harris, M. Katsuki, S. Horie, Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant, *Hum. Mol. Genet.* 11 (2002) 1731–1742.
 - [57] T. Roitbak, C.J. Ward, P.C. Harris, R. Bacallao, S.A. Ness, A. Wandinger-Ness, A polycystin-1 multiprotein complex is disrupted in polycystic kidney disease cells, *Mol. Biol. Cell* 15 (2004) 1334–1346.
 - [58] C.M. Sorenson, Nuclear localization of beta-catenin and loss of apical brush border actin in cystic tubules of bcl-2 Δ mice, *Am. J. Physiol.* 276 (1999) F210–F217.
 - [59] E. Fischer, E. Legue, A. Doyen, F. Nato, J.F. Nicolas, V. Torres, M. Yaniv, M. Pontoglio, Defective planar cell polarity in polycystic kidney disease, *Nat. Genet.* 38 (2006) 21–23.
 - [60] J.A. Jonassen, J. San Agustin, J.A. Folliet, G.J. Pazour, Deletion of IFT20 in the mouse kidney causes misorientation of the mitotic spindle and cystic kidney disease, *J. Cell Biol.* 183 (2008) 377–384.
 - [61] C.M. Karner, R. Chirumamilla, S. Aoki, P. Igarashi, J.B. Wallingford, T.J. Carroll, Wnt9b signaling regulates planar cell polarity and kidney tubule morphogenesis, *Nat. Genet.* 41 (2009) 793–799.
 - [62] V. Patel, L. Li, P. Cobo-Stark, X. Shao, S. Somlo, F. Lin, P. Igarashi, Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia, *Hum. Mol. Genet.* 17 (2008) 1578–1590.
 - [63] S. Saburi, I. Hester, E. Fischer, M. Pontoglio, V. Eremina, M. Gessler, S.E. Quaggin, R. Harrison, R. Mount, H. McNeill, Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease, *Nat. Genet.* 40 (2008) 1010–1015.
 - [64] S. Nishio, X. Tian, A.R. Gallagher, Z. Yu, V. Patel, P. Igarashi, S. Somlo, Loss of oriented cell division does not initiate cyst formation, *J. Am. Soc. Nephrol.* 21 (2010) 295–302.
 - [65] J. Cheng, N. Turkel, N. Hemati, M.T. Fuller, A.J. Hunt, Y.M. Yamashita, Centrosome misorientation reduces stem cell division during ageing, *Nature* 456 (2008) 599–604.
 - [66] T. Arnould, E. Kim, L. Tsiokas, F. Jochimsen, W. Gruning, J.D. Chang, G. Walz, The polycystic kidney disease 1 gene product mediates protein kinase C alpha-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor AP-1, *J. Biol. Chem.* 273 (1998) 6013–6018.
 - [67] S. Nishio, M. Hatano, M. Nagata, S. Horie, T. Koike, T. Tokuhisa, T. Mochizuki, Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation, *J. Clin. Invest.* 115 (2005) 910–918.
 - [68] S. Omori, M. Hida, H. Fujita, H. Takahashi, S. Tanimura, M. Kohno, M. Awazu, Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease, *J. Am. Soc. Nephrol.* 17 (2006) 1604–1614.
 - [69] S.C. Parnell, B.S. Magenheimer, R.L. Maser, C.A. Zien, A.M. Frischauf, J.P. Calvet, Polycystin-1 activation of c-Jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins, *J. Biol. Chem.* 277 (2002) 19566–19572.
 - [70] W. Yu, T. Kong, S. Beaudry, M. Tran, H. Negoro, V. Yanamada, B.M. Denker, Polycystin-1 protein level determines activity of the G(alpha)12/JNK apoptosis pathway, *J. Biol. Chem.* 285 (2010) 10243–10251.
 - [71] A. Togawa, J. Miyoshi, H. Ishizaki, M. Tanaka, A. Takakura, H. Nishioka, H. Yoshida, T. Doi, A. Mizoguchi, N. Matsuura, Y. Niho, Y. Nishimune, S. Nishikawa, Y. Takai, Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha, *Oncogene* 18 (1999) 5373–5380.
 - [72] F.A. Belibi, G. Reif, D.P. Wallace, T. Yamaguchi, L. Olsen, H. Li, G.M. Helmkamp Jr., J.J. Grantham, Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells, *Kidney Int.* 66 (2004) 964–973.
 - [73] K. Hanaoka, W.B. Guggino, cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells, *J. Am. Soc. Nephrol.* 11 (2000) 1179–1187.
 - [74] T. Yamaguchi, S. Nagao, M. Kasahara, H. Takahashi, J.J. Grantham, Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease, *Am. J. Kidney Dis.* 30 (1997) 703–709.
 - [75] T. Yamaguchi, J.C. Pelling, N.T. Ramaswamy, J.W. Eppler, D.P. Wallace, S. Nagao, L.A. Rome, L.P. Sullivan, J.J. Grantham, cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway, *Kidney Int.* 57 (2000) 1460–1471.
 - [76] J.M. Banales, T.V. Masyuk, S.A. Gradilone, A.I. Masyuk, J.F. Medina, N.F. LaRusso, The cAMP effectors Epac and protein kinase A (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD), *Hepatology* (Baltimore, Md) 49 (2009) 160–174.
 - [77] S.N. Kip, L.W. Hunter, Q. Ren, P.C. Harris, S. Somlo, V.E. Torres, G.C. Sieck, Q. Qian, [Ca²⁺]_i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotype, *Circ. Res.* 96 (2005) 873–880.
 - [78] X. Wang, C.J. Ward, P.C. Harris, V.E. Torres, Cyclic nucleotide signaling in polycystic kidney disease, *Kidney Int.* 77 (2010) 129–140.
 - [79] G. Tortora, F. Ciardiello, S. Pepe, P. Tagliaferri, A. Ruggiero, C. Bianco, R. Guarrasi, K. Miki, A.R. Bianco, Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients, *Clin. Cancer Res.* 1 (1995) 377–384.
 - [80] S.M. Yu, Z.J. Cheng, S.C. Kuo, Antiproliferative effects of A02011-1, an adenylyl cyclase activator, in cultured vascular smooth muscle cells of rat, *Br. J. Pharmacol.* 114 (1995) 1227–1235.
 - [81] M. Sutters, T. Yamaguchi, R.L. Maser, B.S. Magenheimer, P.L. St John, D.R. Abrahamson, J.J. Grantham, J.P. Calvet, Polycystin-1 transforms the cAMP growth-responsive phenotype of M-1 cells, *Kidney Int.* 60 (2001) 484–494.
 - [82] T. Yamaguchi, D.P. Wallace, B.S. Magenheimer, S.J. Hempson, J.J. Grantham, J.P. Calvet, Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype, *J. Biol. Chem.* 279 (2004) 40419–40430.
 - [83] T. Yamaguchi, S.J. Hempson, G.A. Reif, A.M. Hedge, D.P. Wallace, Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells, *J. Am. Soc. Nephrol.* 17 (2006) 178–187.
 - [84] X. Wang, P.C. Harris, S. Somlo, D. Battle, V.E. Torres, Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease, *Nephrol. Dial. Transplant.* 24 (2009) 526–534.
 - [85] B.D. Cowley Jr., Calcium, cyclic AMP, and MAP kinases: dysregulation in polycystic kidney disease, *Kidney Int.* 73 (2008) 251–253.
 - [86] T. Yamaguchi, S. Nagao, D.P. Wallace, F.A. Belibi, B.D. Cowley, J.C. Pelling, J.J. Grantham, Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys, *Kidney Int.* 63 (2003) 1983–1994.
 - [87] M. Boca, L. D'Amato, G. Distefano, R.S. Polishchuk, G.G. Germino, A. Boletta, Polycystin-1 induces cell migration by regulating phosphatidylinositol 3-kinase-dependent cytoskeletal rearrangements and GSK3beta-dependent cell mechanical adhesion, *Mol. Biol. Cell* 18 (2007) 4050–4061.
 - [88] E.Y. Park, Y.H. Sung, M.H. Yang, J.Y. Noh, S.Y. Park, T.Y. Lee, Y.J. Yook, K.H. Yoo, K.J. Roh, I. Kim, Y.H. Hwang, G.T. Oh, J.K. Seong, C. Ahn, H.W. Lee, J.H. Park, Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice, *J. Biol. Chem.* 284 (2009) 7214–7222.
 - [89] A. Boletta, Emerging evidence of a link between the polycystins and the mTOR pathways, *Pathogenesis* 2 (2009) 6.
 - [90] W. Lieberthal, J.S. Levine, The role of the mammalian target of rapamycin (mTOR) in renal disease, *J. Am. Soc. Nephrol.* 20 (2009) 2493–2502.
 - [91] T. Weimbs, Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair? *Cell cycle* (Georgetown, Tex) 5 (2006) 2425–2429.
 - [92] C.S. Bonnet, M. Aldred, C. von Ruhland, R. Harris, R. Sandford, J.P. Cheadle, Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis, *Hum. Mol. Genet.* 18 (2009) 2166–2176.
 - [93] T.R. Hartman, D. Liu, J.T. Zilfou, V. Robb, T. Morrison, T. Watnick, E.P. Henske, The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway, *Hum. Mol. Genet.* 18 (2009) 151–163.
 - [94] J.M. Shillingford, N.S. Murcia, C.H. Larson, S.H. Low, R. Hedgepeth, N. Brown, C.A. Flask, A.C. Novick, D.A. Goldfarb, A. Kramer-Zucker, G. Walz, K.B. Piontek, G.G. Germino, T. Weimbs, The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease, *Proc. Natl Acad. Sci. USA* 103 (2006) 5466–5471.
 - [95] V.H. Gattone II, R.M. Sinders, T.A. Hornberger, A.G. Robling, Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis, *Kidney Int.* 76 (2009) 178–182.
 - [96] J.M. Shillingford, K.B. Piontek, G.G. Germino, T. Weimbs, Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1, *J. Am. Soc. Nephrol.* 21 (2010) 489–497.
 - [97] Y. Tao, J. Kim, R.W. Schrier, C.L. Edelstein, Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease, *J. Am. Soc. Nephrol.* 16 (2005) 46–51.
 - [98] P.R. Wahl, A.L. Serra, M. Le Hir, K.D. Molle, M.N. Hall, R.P. Wuthrich, Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD), *Nephrol. Dial. Transplant.* 21 (2006) 598–604.
 - [99] M. Wu, A. Arcaro, Z. Varga, A. Vogetseder, M. Le Hir, R.P. Wuthrich, A.L. Serra, Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease, *Am. J. Physiol.* 297 (2009) F1597–F1605.
 - [100] I. Zafar, F.A. Belibi, Z. He, C.L. Edelstein, Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD), *Nephrol. Dial. Transplant.* 24 (2009) 2349–2353.
 - [101] R. Dere, P.D. Wilson, R.N. Sandford, C.L. Walker, Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR, *PLoS ONE* 5 (2010) e9239.
 - [102] E. Kleymenova, O. Ibragimov-Beskrovnaia, H. Kugoh, J. Everitt, H. Xu, K. Kiguchi, G. Landes, P. Harris, C. Walker, Tuberin-dependent membrane localization of

- polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene, *Mol. Cell* 7 (2001) 823–832.
- [103] G. Distefano, M. Boca, I. Rowe, C. Wodarczyk, L. Ma, K.B. Piontek, G.G. Germino, P.P. Pandolfi, A. Boletta, Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1, *Mol. Cell. Biol.* 29 (2009) 2359–2371.
- [104] D.C. Fischer, U. Jacoby, L. Pape, C.J. Ward, E. Kuwertz-Broeking, C. Renken, H. Nizze, U. Querfeld, B. Rudolph, D.E. Mueller-Wiefel, C. Bergmann, D. Haffner, Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD), *Nephrol. Dial. Transplant.* 24 (2009) 1819–1827.
- [105] A.L. Serra, D. Poster, A.D. Kistler, F. Krauer, S. Raina, J. Young, K.M. Rentsch, K.S. Spanaus, O. Senn, P. Kristanto, H. Scheffel, D. Weishaupt, R.P. Wuthrich, Sirolimus and kidney growth in autosomal dominant polycystic kidney disease, *N Engl J. Med.* 363 (2010) 820–829.
- [106] G. Walz, K. Budde, M. Mannaa, J. Nurnberger, C. Wanner, C. Sommerer, U. Kunzendorf, B. Banas, W.H. Horl, N. Obermuller, W. Arns, H. Pavenstadt, J. Gaedeke, M. Buchert, C. May, H. Gschaidmeier, S. Kramer, K.U. Eckardt, Everolimus in patients with autosomal dominant polycystic kidney disease, *N Engl J. Med.* 363 (2010) 830–840.
- [107] T. Watnick, G.G. Germino, mTOR inhibitors in polycystic kidney disease, *N Engl J. Med.* 363 (2010) 879–881.